Innovation Pharmaceuticals Inc.

IPIX

US45782D1000

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 12:24:20 23/05/2024 am IST			5-day change	1st Jan Change
0.0015 ^USD	0.00%		0.00%	-69.39%

01/02	Innovation Pharmaceuticals Inc. Announces Resignation of Board Members	CI
2023	Alfasigma S.p.A. and Innovation Pharmaceuticals Inc. Terminate Exclusive License Agreement	CI

Cellceutix Corporation will Change its Name to Innovation Pharmaceuticals Inc

June 09, 2017 at 09:30 am IST

Effective June 09, 2017, Cellceutix Corporation will change its name to Innovation Pharmaceuticals Inc.

Latest news about Innovation Pharmaceuticals Inc.

Innovation Pharmaceuticals Inc. Announces Resignation of Board Members	01/02	CI
Alfasigma S.p.A. and Innovation Pharmaceuticals Inc. Terminate Exclusive License Agreement	06/12	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	21/11	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	28/23/28	CI
Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases	21/23/21	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	15/23/15	CI
Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID Affiliated and Other Academic Researchers	15/23/15	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	16/23/16	CI
Innovation Pharmaceuticals Provides an Update on Ongoing Research on the Broad-Spectrum Antifungal Activity of Brilacidin	13/22/13	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	11/22/11	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended June 30, 2022	29/22/29	CI
Innovation Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt	28/22/28	CI
Innovation Pharmaceuticals Inc. acquired an unknown minority stake in Squalus Medical.	15/22/15	CI
Squalus Medical announced that it has received $4.999968 million in funding from Innovation Pharmaceuticals Inc., and other investors	09/22/09	CI
Innovation Pharmaceuticals Inc. announced a financing transaction	09/22/09	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	14/22/14	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021	15/22/15	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended September 30, 2021	10/21/10	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended June 30, 2021	28/21/28	CI
Innovation Pharmaceuticals Provides Additional Information Regarding the Status of Its Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial of Brilacidin for the Treatment of Moderate-To-Severe Covid-19 in Hospitalized Patients	12/21/12	CI
Innovation Pharmaceuticals Announces New In Vitro Data Supporting Brilacidin’s Broad-Spectrum Antiviral Potential Presented at the American Society of Virology’s Annual Meeting	22/21/22	CI
Innovation Pharma Announces New Brilacidin Antiviral Research on Non-SARS-CoV-2 Endemic Viral Diseases to be Presented at the 2021 Military Health System Research Symposium	18/21/18	CI
Innovation Pharma Completes Enrollment in Phase 2 Clinical Trial for COVID-19	03/21/03	CI
Innovation Pharmaceuticals Announces Patient Enrollment Reaches 90% in Innovation Pharmaceuticals Phase 2 Clinical Trial of Brilacidin for Covid-19	27/21/27	CI
Innovation Pharma Surpasses 50% Enrollment in Phase 2 Clinical Trial of Brilacidin for COVID-19	28/21/28	CI

Chart Innovation Pharmaceuticals Inc.

Duration

Period

More charts

Innovation Pharmaceuticals Inc. is a clinical stage pharmaceutical company developing therapies with anti-infective, oncology, anti-inflammatory and dermatology applications. The Companyâs lead drug candidate, Brilacidin, is in a class of compounds called defensin-mimetics, small compounds that mimic the structure and function of defensins, also known as host defense peptides. The Company is primarily focused on business development for the advancement of Brilacidin in the treatment of infectious diseases and oral mucositis. Its ongoing activities include Brilacidin drug manufacturing, scientific report writing, and supportive research activities. Brilacidin is also developed as a treatment in more extensive forms of inflammatory bowel disease (IBD). It is engaged in developing an image guided surgical laser platform, through BT BeaMedical Technologies Ltd. It is also engaged in business development and licensing initiatives with specialty and global pharmaceutical companies.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
INNOVATION PHARMACEUTICALS INC.	-69.39%	8L
VERTEX PHARMACEUTICALS INCORPORATED	+9.99%	12TCr
REGENERON PHARMACEUTICALS, INC.	+12.01%	11TCr
BIONTECH SE	-3.07%	2.47TCr
ARGENX SE	-0.93%	2.2TCr
GENMAB A/S	-5.71%	1.93TCr
BEIGENE, LTD.	-6.90%	1.76TCr
WUXI APPTEC CO., LTD.	-39.36%	1.73TCr
NEUROCRINE BIOSCIENCES, INC.	+5.82%	1.4TCr
SAREPTA THERAPEUTICS, INC.	+33.05%	1.21TCr